- Home
- ACT vs BPMC Comparison
ACT vs BPMC Comparison
Compare ACT & BPMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACT
- BPMC
- Stock Information
- Founded
- ACT 1981
- BPMC 2008
- Country
- ACT United States
- BPMC United States
- Employees
- ACT N/A
- BPMC N/A
- Industry
- ACT Specialty Insurers
- BPMC Biotechnology: Pharmaceutical Preparations
- Sector
- ACT Finance
- BPMC Health Care
- Exchange
- ACT Nasdaq
- BPMC Nasdaq
- Market Cap
- ACT 5.3B
- BPMC 5.8B
- IPO Year
- ACT 2021
- BPMC 2015
- Fundamental
- Price
- ACT $36.13
- BPMC $97.17
- Analyst Decision
- ACT Buy
- BPMC Buy
- Analyst Count
- ACT 4
- BPMC 21
- Target Price
- ACT $37.75
- BPMC $124.05
- AVG Volume (30 Days)
- ACT 796.2K
- BPMC 973.2K
- Earning Date
- ACT 04-30-2025
- BPMC 05-01-2025
- Dividend Yield
- ACT 2.05%
- BPMC N/A
- EPS Growth
- ACT 9.98
- BPMC N/A
- EPS
- ACT 4.44
- BPMC N/A
- Revenue
- ACT $1,216,974,000.00
- BPMC $562,121,000.00
- Revenue This Year
- ACT $3.68
- BPMC $44.85
- Revenue Next Year
- ACT $4.25
- BPMC $32.06
- P/E Ratio
- ACT $8.20
- BPMC N/A
- Revenue Growth
- ACT 4.52
- BPMC 99.19
- 52 Week Low
- ACT $29.37
- BPMC $73.04
- 52 Week High
- ACT $37.56
- BPMC $121.90
- Technical
- Relative Strength Index (RSI)
- ACT 55.56
- BPMC 59.54
- Support Level
- ACT $35.31
- BPMC $87.03
- Resistance Level
- ACT $36.95
- BPMC $104.86
- Average True Range (ATR)
- ACT 0.87
- BPMC 3.86
- MACD
- ACT 0.04
- BPMC 1.24
- Stochastic Oscillator
- ACT 50.02
- BPMC 64.38
About ACT Enact Holdings Inc.
Enact Holdings Inc is a private mortgage insurance company serving the United States housing finance market. The principal mortgage insurance customers are originators of residential mortgage loans who determine which mortgage insurer or insurers will be used for the placement of mortgage insurance written on loans originated. The company is engaged in writing and assuming residential mortgage guaranty insurance.
About BPMC Blueprint Medicines Corporation
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.